Shots:

• Kiniksa to receive $22M up front including $12M for the territory license of rilonacept and $10M for mavrilimumab and is eligible to receive ~$640M in development, regulatory and sales-based milestones along with royalties
• Huadong Medicine will get an exclusive right & will be responsible for the development and commercialization of Arcalyst and mavrilimumab in the Asia Pacific region including Greater China, South Korea, Australia, and 18 other countries (Ex-Japan)
• Kiniksa will retain development and commercialization rights to the licensed products outside the territory. Arcalyst received the BTD & ODD from the US FDA for the treatment of recurrent pericarditis

 Ref: Kiniksa | Image: Linkedin